Management of Immune Checkpoint Inhibitor Toxicities

被引：0

作者：

Durrechou, Quentin ^{[1
]}

Domblides, Charlotte ^{[1
,2
]}

Sionneau, Baptiste ^{[1
]}

Lefort, Felix ^{[1
]}

Quivy, Amandine ^{[1
]}

Ravaud, Alain ^{[1
]}

Gross-Goupil, Marine ^{[1
]}

Daste, Amaury ^{[1
]}

机构：

[1] Univ Bordeaux, CHU Bordeaux, Hop St Andre, Dept Med Oncol, 1 Rue Jean Burguet, F-33000 Bordeaux, France

[2] Bordeaux Univ, CNRS UMR 5164, ImmunoConcEpt, F-33076 Bordeaux, France

来源：

CANCER MANAGEMENT AND RESEARCH | 2020年 / 12卷

关键词：

immune check point inhibitor; toxicity; corticosteroids; immunosuppressive treatments; STAGE-III MELANOMA; ADVERSE EVENTS; PREEXISTING AUTOIMMUNE; METASTATIC MELANOMA; COMBINED NIVOLUMAB; OLDER-ADULTS; DOUBLE-BLIND; IPILIMUMAB; CANCER; SAFETY;

D O I：

10.2147/CMAR.S219755

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint inhibitors (ICIs) have radically changed the clinical outcome of several cancers with durable responses. CTLA-4 (cytotoxic T lymphocyte antigen-4), PD-1 (programmed cell death protein 1) or PDL-1 (programmed cell death ligand protein 1) represent ICIs that can be used as monotherapy or in combination with other agents. The toxicity profiles of ICIs differ from the side effects of cytotoxic agents and come with new toxicities like immune-related adverse events. Typically, these toxicities occur in all organs. However, the main organs affected are the skin, digestive, hepatic, lungs, rheumatologic, and endocrine. Most of the immune toxicity that occurs is low grade but some more severe toxicities can occur that require a rapid diagnosis and appropriate treatment. The recognition of symptoms by physicians and patient is necessary to resolve them rapidly and adapt treatment to allow the toxicity to resolve.

引用

页码：9139 / 9157

页数：19

共 103 条

[11] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[12] Immune and Molecular Correlates in Melanoma Treated With Immune Checkpoint Blockade [J].

Byrne, Elizabeth H. ;

Fisher, David E. .

CANCER, 2017, 123 :2143-2153

[13] Immune regulation by glucocorticoids [J].

Cain, Derek W. ;

Cidlowski, John A. .

NATURE REVIEWS IMMUNOLOGY, 2017, 17 (04) :233-247

[14] Challenges in lung cancer therapy during the COVID-19 pandemic [J].

Calabro, Luana ;

Peters, Solange ;

Soria, Jean-Charles ;

Di Giacomo, Anna Maria ;

Barlesi, Fabrice ;

Covre, Alessia ;

Altomonte, Maresa ;

Vegni, Virginia ;

Gridelli, Cesare ;

Reck, Martin ;

Rizvi, Naiyer ;

Maio, Michele .

LANCET RESPIRATORY MEDICINE, 2020, 8 (06) :542-544

[15] Glucocorticoid receptor translational isoforms underlie maturational stage-specific glucocorticoid sensitivities of dendritic cells in mice and humans [J].

Cao, Yun ;

Bender, Ingrid K. ;

Konstantinidis, Athanasios K. ;

Shin, Soon Cheon ;

Jewell, Christine M. ;

Cidlowski, John A. ;

Schleimer, Robert P. ;

Lu, Nick Z. .

BLOOD, 2013, 121 (09) :1553-1562

[16] Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis [J].

Cappelli, Laura C. ;

Dorak, Mehmet T. ;

Bettinotti, Maria P. ;

Bingham, Clifton O., III ;

Shah, Ami A. .

RHEUMATOLOGY, 2019, 58 (03) :476-480

[17] Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade Insights into Pathogenesis from an Autopsy Series [J].

Caturegli, Patrizio ;

Di Dalmazi, Giulia ;

Lombardi, Martina ;

Grosso, Federica ;

Larman, H. Benjamin ;

Larman, Tatianna ;

Taverna, Giacomo ;

Cosottini, Mirco ;

Lupi, Isabella .

AMERICAN JOURNAL OF PATHOLOGY, 2016, 186 (12) :3225-3235

[18] Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease [J].

Cavalcante, Ludimila ;

Amin, Asim ;

Lutzky, Jose .

CANCER MANAGEMENT AND RESEARCH, 2015, 7 :47-50

[19]

Chalabi M, 2020, ANN ONCOL, V31, P525, DOI [10.1016/j.annoc.2020.01.006, 10.1016/j.annonc.2020.01.006]

[20] Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper [J].

Champiat, S. ;

Lambotte, O. ;

Barreau, E. ;

Belkhir, R. ;

Berdelou, A. ;

Carbonnel, F. ;

Cauquil, C. ;

Chanson, P. ;

Collins, M. ;

Durrbach, A. ;

Ederhy, S. ;

Feuillet, S. ;

Francois, H. ;

Lazarovici, J. ;

Le Pavec, J. ;

De Martin, E. ;

Mateus, C. ;

Michot, J. -M. ;

Samuel, D. ;

Soria, J. -C. ;

Robert, C. ;

Eggermont, A. ;

Marabelle, A. .

ANNALS OF ONCOLOGY, 2016, 27 (04) :559-574

← 1 2 3 4 5 6 7 8 9 10 →